<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01574430</url>
  </required_header>
  <id_info>
    <org_study_id>PDTCSC-CHINA</org_study_id>
    <nct_id>NCT01574430</nct_id>
  </id_info>
  <brief_title>Study of Photodynamic Therapy (PDT) in Patients With Central Serous Chorioretinopathy (CSC)</brief_title>
  <official_title>A Randomized, Double-masked, Multicenter, Controlled Study of Photodynamic Therapy in Patients With Central Serous Chorioretinopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University People's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and efficacy of PDT at 30% verteporfin
      dose in the treatment of CSC.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in BCVA</measure>
    <time_frame>1 week,2 weeks,3 weeks,1 month,3months, 6 months, 1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Leakage at RPE level in FA</measure>
    <time_frame>1 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in central retinal thickness</measure>
    <time_frame>1 week,2 weeks,3 weeks,1 month,3months, 6 months, 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence rate of adverse event</measure>
    <time_frame>1 week,2 weeks,3 weeks,1 month,3months, 6 months, 1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">131</enrollment>
  <condition>Central Serous Chorioretinopathy</condition>
  <arm_group>
    <arm_group_label>50% dose PDT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients in this group was given 50% verteporfin dose PDT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>30% dose PDT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients in this group was given 30% verteporfin dose PDT</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PDT</intervention_name>
    <description>30% or 50% verteporfin dose PDT was given to patients with CSC</description>
    <arm_group_label>50% dose PDT</arm_group_label>
    <arm_group_label>30% dose PDT</arm_group_label>
    <other_name>photodynamic therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with CSC

          -  patients signed the ICF

          -  patients with course of CSC less than 6 months

          -  patients did not undertake any treatment for CSC

        Exclusion Criteria:

          -  patients with porphyria

          -  patients allergic to verteporfin

          -  pregnant or nursing women

          -  poor patients compliance

          -  sever liver dysfunction

          -  dioptric media opacities which make it difficult to exam fundus
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mingwei Zhao, M.D</last_name>
    <role>Study Director</role>
    <affiliation>People's Hospital of Peking University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Youxin Chen, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Feng Zhang, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Tongren Hospital of Capital Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hong Dai, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xiaoxin Li, M.D</last_name>
    <role>Study Chair</role>
    <affiliation>People's Hospital of Peking University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>People's Hospital of Peking University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 8, 2012</study_first_submitted>
  <study_first_submitted_qc>April 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2012</study_first_posted>
  <last_update_submitted>August 15, 2016</last_update_submitted>
  <last_update_submitted_qc>August 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University People's Hospital</investigator_affiliation>
    <investigator_full_name>Mingwei Zhao</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Central Serous Chorioretinopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Verteporfin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

